Niki BioSolutions Partners with Fios Genomics to Advance Alzheimer’s Testing Pipeline

Niki BioSolutions, a clinical-stage life sciences company, has partnered with Fios Genomics to accelerate its Alzheimer’s disease testing pipeline. The collaboration aims to leverage Fios Genomics' advanced bioinformatics and biostatistical expertise to refine target and biomarker decisions across Niki BioSolutions' platform.

Under the agreement, Fios Genomics will analyze and interpret complex biological datasets generated in Niki BioSolutions' Alzheimer’s disease program. This analysis is crucial for identifying meaningful biological signals, validating potential targets and biomarkers, and making informed decisions at each stage of development. The datasets, which include genomic, transcriptomic, and proteomic data, are expected to be large and complex, underscoring the importance of robust and reliable analytical support.

Alidad Mireskandari, Ph.D., President and Chief Operating Officer of Niki BioSolutions, emphasized the significance of this partnership. "The datasets generated in this project are large and complex, and getting the analysis right is critical to the decisions we make next. Fios Genomics has a strong track record of delivering high-quality, independent bioinformatics and statistical analysis for life sciences organizations, and its expertise allows our team to stay focused on advancing the science."

The partnership is expected to inform target and biomarker prioritization and support the design of subsequent validation studies within Niki BioSolutions' pipeline. The company's focus on unmet medical needs and genomic and biomarker testing solutions positions it to bring new options to people at risk of or living with Alzheimer’s disease.

Niki BioSolutions, based in Princeton, New Jersey, and DiamiR Biosciences Corp., its wholly owned subsidiary, are committed to supporting precision medicine across a range of therapeutic areas, including brain health and oncology. The company's CLIA-certified, CAP-accredited laboratory combines proprietary technologies with a commitment to scientific rigor to support precision medicine.

Fios Genomics, a specialist provider of bioinformatics and biostatistics services, supports research and development programs with data analysis and interpretation across genomics, transcriptomics, proteomics, and other high-throughput data types. Headquartered in Edinburgh, United Kingdom, Fios Genomics brings deep experience in the analysis of complex biological datasets and rigorous statistical methodology to the partnership.

The collaboration between Niki BioSolutions and Fios Genomics underscores the critical role of advanced analytical tools in advancing Alzheimer’s disease research. By leveraging Fios Genomics' expertise, Niki BioSolutions aims to accelerate the development of new diagnostic and therapeutic solutions for Alzheimer’s disease, addressing one of the most significant unmet needs in medicine.